Department of Pharmaceutical Health Services Research, University of Maryland, Baltimore, MD, USA.
Health Aff (Millwood). 2013 Jul;32(7):1212-20. doi: 10.1377/hlthaff.2012.0848.
Targeting efforts to improve medication adherence, especially among people with high health needs, can improve health and lower health care spending. To this end, Medicare requires that insurance plans that provide prescription drug (Part D) coverage offer specialized medication therapy management services to optimize medication use for enrollees with high drug costs, multiple chronic diseases, and multiple covered drugs. We analyzed a large random sample of Part D enrollees with diabetes, heart failure, and chronic obstructive pulmonary disease, to see whether poor adherence to recommended drugs was associated with higher Medicare costs. We found that beneficiaries with poor adherence had higher costs, ranging from $49 to $840 per month for patients with diabetes, for example. However, such beneficiaries were not uniformly more likely than others to be eligible for medication therapy management services. Aligning medication therapy management eligibility with a metric such as potentially preventable future costs holds promise for both improving the quality of care and reducing spending.
目标是努力提高药物依从性,特别是在高健康需求人群中,这可以改善健康状况并降低医疗保健支出。为此,医疗保险要求提供处方药物(Part D)覆盖范围的保险计划为高药物费用、多种慢性病和多种覆盖药物的参保者提供专门的药物治疗管理服务,以优化药物使用。我们分析了大量患有糖尿病、心力衰竭和慢性阻塞性肺疾病的 Part D 参保者的随机样本,以了解推荐药物的依从性差是否与更高的医疗保险费用相关。我们发现,药物依从性差的受益人的费用更高,例如,患有糖尿病的患者每月的费用从 49 美元到 840 美元不等。然而,与其他人相比,此类受益人的药物治疗管理服务资格并不普遍更有可能。根据潜在可预防的未来成本等指标来调整药物治疗管理的资格,有望提高护理质量并降低支出。